Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARG-HIT-CVD argatroban in heparin-induced thrombocytopenia
jRCT1091220001Completed
- Sponsor
- National Cerebral and Cardiovascular Center
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of argatroban in heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITT), sponsored by National Cerebral and Cardiovascular Center. Primary endpoint: Incidence of thrombosis, amputation, and death. Started Dec 2005; status: completed.
02
Drugs
argatroban
03
Conditions
heparin-induced thrombocytopenia (HIT)heparin-induced thrombocytopenia with thrombosis (HITT)
Beyond the preview
Go deeper on jRCT1091220001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220001.